- Investment underlines BASF’s commitment to the health care industry
- Softex® is a dispersion used in the medical glove production
As part of the efforts to support the increasing demand for medical gloves globally due to COVID-19 pandemic, BASF is planning to double its Softex® production capacity at its Cimanggis site in Indonesia. This expansion reiterates BASF’s continued commitment to Asia Pacific and specifically to customers in the medical glove industry that are playing a very pivotal role during the COVID-19 pandemic.
Softex dispersion is a critical material used in medical exam glove production, and it is being recognized throughout the APAC region for helping glove producers to deliver high quality gloves.
“Since its establishment in 1979, the Cimanggis site is an important production facility for the region. BASF has also upgraded its facilities to enable the supply of high-quality materials used in the production for medical gloves. The COVID-19 pandemic has driven a high demand for medical gloves globally, from 340 billion pieces in 2019 to 500 billion pieces in 2021¹. And BASF remains committed to support customers and societal needs, especially during this period,” said Dr. Laszlo Szarvas, Vice President, Business Management Home Care, I&I and Industrial Formulators, Care Chemicals, BASF Asia Pacific.
“ASEAN is an important medical glove manufacturing hub with global reach. In close collaboration with our customers, BASF has expanded new technical pathways in major fast-growing medical glove manufacturing markets, located in ASEAN and China. BASF’s decision to expand Softex® production capacity demonstrates that we are committed to ensuring supply reliability,” said Dr. Laszlo Szarvas.
BUY US A COFFEE
Note to readers:
- Please follow us on LinkedIn ,Twitter and YouTube and subscribe to our website and receive notifications of new posts by email.
- Please click the share buttons below and make a comment.